# US 2013/0156782 A1 · Monoclonal Antibodies for Treatment of Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156782 A1
- Document ID: US20130156782A1
- Status: Published application
- Kind: A1
- Application number: 13/710,828
- Filed: 2012-12-11
- Published: 2013-06-20
- Earliest claimed: 2007-03-14
- Assignees: Ganymed Pharmaceuticals AG; Johannes Gutenberg-Universitat Mainz
- Inventors: Ugur Sahin; Michael Koslowski; Ozlem Tureci
- Web page: https://patentgrep.com/patent/US20130156782A1

## CPC

- C07K 16/30: from tumour cells
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 16/18: against material from animals or humans
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.

## Claims

### Claim at position 1

-35. (canceled)

### Claim 36

An isolated antibody having the ability of binding to a protein comprising the amino acid sequence of SEQ ID NO: 2 and mediating inhibition of proliferation of cells, wherein said cells express a protein comprising the amino acid sequence of SEQ ID NO: 2 and/or are characterized by association of a protein comprising the amino acid sequence of SEQ ID NO: 2 with their cell surface.

### Claim 37 (depends on 36)

The isolated antibody of claim 36 wherein said inhibition of proliferation of said cells is induced by binding of said antibody to a protein comprising the amino acid sequence of SEQ ID NO: 2 expressed by said cells and/or associated with the surface of said cells.

### Claim 38 (depends on 36)

The isolated antibody of claim 36 wherein said antibody binds to the extracellular domain of a protein comprising the amino acid sequence of SEQ ID NO: 2 expressed by said cells and/or associated with the surface of said cells.

### Claim 39 (depends on 36)

The isolated antibody of claim 36 wherein said cells are cancer cells.

### Claim 40 (depends on 39)

The isolated antibody of claim 39, wherein said cancer cells are selected from the group consisting of tumorigenic breast, lung, gastric, ovarian, liver, colon, pancreatic, esophageal, head-neck, renal, prostate and hepatocellular cancer cells.

### Claim 41 (depends on 36)

The isolated antibody of claim 36 which is a monoclonal, chimeric, human or humanized antibody, or an antigen-binding fragment of an antibody.

### Claim 42 (depends on 36)

The isolated antibody of claim 36, selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, a secretory IgA, an IgD, and an IgE antibody.

### Claim 43 (depends on 42)

The isolated antibody of claim 42 selected from the group consisting of an IgG2a and an IgG2b antibody.

### Claim 44 (depends on 36)

The isolated antibody of claim 36 wherein the amino acid sequence of said protein consists of the amino acid sequence according to SEQ ID NO: 2.

### Claim 45 (depends on 36)

The isolated antibody of claim 36 wherein the antibody binds specifically to a protein comprising the amino acid sequence of SEQ ID NO: 2.

### Claim 46 (depends on 36)

The isolated antibody of claim 36 which binds to native epitopes of a protein comprising the amino acid sequence of SEQ ID NO: 2 present on the surface of living cells.

### Claim 47 (depends on 36)

The isolated antibody of claim 36 wherein said protein comprising the amino acid sequence of SEQ ID NO: 2 is expressed on the surface of said cells.

### Claim 48 (depends on 36)

The isolated antibody of claim 36 which is obtainable by a method comprising the step of immunizing an animal with a protein or peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2-10 and 35-79, or an immunogenic fragment or derivative thereof, or a nucleic acid or host cell expressing said protein or peptide, or immunogenic fragment or derivative thereof.

### Claim 49

An isolated antibody produced by a clone deposited under the accession no. DSM ACC2826 (9B6-2A9), DSM ACC2824 (59D6-2F2), DSM ACC2823 (78H11-1H6), DSM ACC2895 (22-1A-1), DSM ACC2893 (22-2A-1), DSM ACC2896 (22-9B-1), DSM ACC2897 (23-33A-1), DSM ACC2891 (23-19A-1), DSM ACC2892 (4A12 2D4 1A1 0), or DSM ACC2898 (4E9 1D12 2D4).

### Claim 50 (depends on 36)

A hybridoma capable of producing the antibody of claim 36.

### Claim 51

A hybridoma deposited under the accession no. DSM ACC2826 (9B6-2A9), DSM ACC2824 (59D6-2F2), DSM ACC2823 (78H11-1H6), DSM ACC2895 (22-1A-1), DSM ACC2893 (22-2A-1), DSM ACC2896 (22-9B-1), DSM ACC2897 (23-33A-1), DSM ACC2891 (23-19A-1), DSM ACC2892 (4A12 2D4 1A10), or DSM ACC2898 (4E9 1D12 2D4).

### Claim 52 (depends on 36)

A conjugate comprising an antibody of claim 36, coupled to a therapeutic agent

### Claim 53 (depends on 52)

The conjugate of claim 52, wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent.

### Claim 54 (depends on 49)

A conjugate comprising an antibody of claim 49, coupled to a therapeutic agent

### Claim 55 (depends on 54)

The conjugate of claim 54, wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent.

### Claim 56 (depends on 36)

A pharmaceutical composition comprising an antibody of claim 36, and a pharmaceutically acceptable carrier.

### Claim 57 (depends on 49)

A pharmaceutical composition comprising an antibody of claim 49, and a pharmaceutically acceptable carrier.

### Claim 58 (depends on 52)

A pharmaceutical composition comprising a conjugate of claim 52, and a pharmaceutically acceptable carrier.

### Claim 59 (depends on 54)

A pharmaceutical composition comprising a conjugate of claim 54, and a pharmaceutically acceptable carrier.
